Vast Therapeutics Announces Series A Funding

Partnership with Shionogi Ltd Includes Collaboration for Development of Proprietary Nitric Oxide Powder Technology for Antimicrobial Resistant Bacteria in Respiratory Applications DURHAM, N.C., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Venture Capital Vast Therapeutics, KNOW Bio, nitric oxide, cystic fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news